Crossmark

The impact of extended half-life versus conventional factor product on hemophilia caregiver burden

Crossref DOI link: https://doi.org/10.1007/s11136-018-1792-9

Published Online: 2018-02-01

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Schwartz, Carolyn E.

Powell, Victoria E.

Su, Jun

Zhang, Jie

Eldar-Lissai, Adi
Funding

Funding for this research was provided by:

Biogen

Swedish Orphan Biovitrum AB
License Information

Text and Data Mining valid from 2018-02-01
More Information

Article History

Accepted: 20 January 2018

First Online: 1 February 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest. Dr. Su was an employee and a shareholder of Biogen and is an employee and a shareholder of Bioverativ. Dr. Eldar-Lissai was an employee and a shareholder of Biogen at the time the study was conducted.